SLC5A2 and diabetes mellitus: This disorder is identified in people with DM and whilst the evidence to suggest that it may be increased in people treated with SGLT-2 inhibitors is limited to post-marketing surveillance [49], all people starting SGLT-2 inhibitors should be advised on the symptoms of Fournier’s gangrene and what to do if they develop such symptoms.